Investors

Press Releases

Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment
Endonovo Therapeutics Files Patent on Bioelectronic Technology, Devices and Therapies
Endonovo Therapeutics Developing Non-Invasive Bioelectronic Therapy for Urinary Incontinence
Endonovo Therapeutics to Develop Next Generation, Off-The-Shelf, Cell Free Regenerative Products
Endonovo Therapeutics Affects 1-for-100 Reverse Stock Split
Endonovo Therapeutics Changes Ticker Symbol to ENDV
Endonovo Therapeutics Signs Funding Agreement for $10 Million
Hanover Portfolio Acquisitions Changes Its Name to Endonovo Therapeutics
RSS